Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Expenses (2017 - 2025)

Aclaris Therapeutics has reported Accumulated Expenses over the past 9 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $5.3 million for Q4 2025, up 6.41% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 6.41% YoY), and the annual figure for FY2025 was $5.3 million, up 6.41%.
  • Accumulated Expenses for Q4 2025 was $5.3 million at Aclaris Therapeutics, down from $9.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ACRS hit a ceiling of $15.2 million in Q3 2023 and a floor of $502000.0 in Q3 2024.
  • Median Accumulated Expenses over the past 5 years was $4.4 million (2023), compared with a mean of $5.3 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 96.69% in 2024 and later skyrocketed 1849.0% in 2025.
  • Aclaris Therapeutics' Accumulated Expenses stood at $2.6 million in 2021, then surged by 228.34% to $8.7 million in 2022, then crashed by 55.06% to $3.9 million in 2023, then rose by 27.34% to $5.0 million in 2024, then grew by 6.41% to $5.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $5.3 million (Q4 2025), $9.8 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.